Source: Greenwich Connecticut Economics Forum, Stay up date with the All Things Denner Blog. Ironwood remains open to continuing a constructive dialogue.”. The move came under pressure from activist investor Alex Denner â who founded investment fund Sarissa Capital Management â to increase the value of ⦠Medicines Co. is restructuring its board, cutting to 7 members from 12. Highest soloistic demands The basis of the historical bore shape are concepts... Dr. Denner has led Sarissa’s involvement in some of biopharma’s most successful strategic transactions and activist campaigns, including the sale of Idenix to Merck, the sale of ARIAD Pharmaceuticals to Takeda and the spinoff from Biogen and subsequent sale of Bioverativ to Sanofi. Alexander Denner owns over 50,000 units of Biogen stock worth over $1,204,041,080 and over the last 11 years he sold BIIB stock worth over $1,800,788. Alex Denner has been investing in healthcare companies for the past two decades. It may take a while and require some patience, but, if Denner has 30%, the endgame will be a buyout. Sarissa Capital Management LP Info: Size ($ in 1000's) At 12/31/2020: $979,780 At 09/30/2020: $849,434 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. Alex Denner Hedge fund operator. That's all I need to know given how things went for ARIA and MDCO where he took a similar stake. And who will follow his game book on their own deals? Ironwood (Nasdaq: IRWD) said Monday that Sarissa Capital Management located at 660 Steamboat Road Greenwich, Connecticut informed the company that it plans to nominate Denner, its chief investment officer, to the drugmaker’s board of directors. The estimated Net Worth of Alexander J Denner is at least $1.21 Billion dollars as of 28 June 2019. Recently Oregon became the first state to legalize psychedelic mushrooms which are shown to have promising results in treating depression, addiction, and PTSD in early stage academic studies. But Alex Denner has been credited as the power behind the throne, a key player in the turnaround story of several top life sciences companies and a figure now promising to start stealing his own headlines now that he’s jumped Icahn’s ship to helm his own hedge fund. Denner has created the template for the modern-day biotech turnaround story. Sarissa Capital Management is a Greenwich, Connecticut-based activist hedge fund established in 2012 by its current chief investment officer, Dr. ⦠Ironwood also stated they will consider the input of shareholders before its board makes a recommendation on the nomination. In 2013, he founded Sarissa Capital Management LP, a registered investment advisor, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the healthcare sector. In the end he was the one that got the cheers when Sanofi stepped up with a $20 billion buyout. The big question now is where he plans to play next. Sarissa Capital & Alex Denner. Her passion for the arts emerged at a young age, making her explore all its forms- acting, singing, writing, drawing, painting and even cooking. At Insider Monkey we leave no stone unturned when looking for the next great investment idea. Alex Denner, chief investment officer and founding partner of Sarissa Capital Management LP, speaks at the Next Wave Sohn during the 20th Annual Sohn... Pictured: Alex Denner, CIO of Sarissa Capital Management, at the 34th annual J.P. Morgan Health Care Conference on January 12, 2016 in ⦠Alex Denner, founder of Sarissa Capital, has helped bring about sales of biotech firms and ousted CEOs in at least five instances over the past decade, including at Genzyme and Biogen Idec. Almost immediately, they set out in full-time missionary work. Alex Denner, Ph.D., has been investing in healthcare companies for the past two decades. Sarissa discloses 33% ownership of ITRM Heatmaps of the top 20 holdings and a list of the largest trades made by Sarissa Capital Management, the hedge fund managed by Alex-Denner. Sarissa focuses on improving the strategies of healthcare companies to enhance shareholder value. Alex Denner Chief Investment Officer at Sarissa Capital Greater New York City Area 500+ connections Sarissa Capital Management, managed by Alex Denner, initiated the largest position in Alkermes Plc (NASDAQ:ALKS). We analyze the mood of a select group of the best investors in the world who spend a great deal of time and resources on researching companies. Sarissa Capital Management LP, the hedge fund of activist investor Alex Denner, boosted its stake in Astex Pharmaceuticals Inc. after the cancer-drug maker accepted an ⦠Ironwood Pharmaceuticals told shareholders Monday that itâs learned biotech activist investor Alex Denner of Sarissa Capital is seeking to join its ⦠As an activist investor, he works passionately on reconstructing companies’ methodologies in order to maximize shareholder value. Source: The Official John Denner Website "All Things Denner. Carl Icahn may have received most of the credit, and certainly the lion’s share of the cash, created by his high-profile biotech raiding parties. He served as the Managing Director at various Carl C. Icahn affiliated entities, including Icahn Partners and Senior Managing Director at Icahn Capital, Portfolio Manager for healthcare investments at Viking Global Investors, Managed Healthcare and Biotechnology Mutual Funds at Morgan Stanley Investment Management, Served as the Chairman of The Board at ARIAD Pharmaceuticals, and has been an Independent Director of Biogen Inc since 2009. Alex Denner of Sarissa Capital Management. In 2013 Mr. Denner founded Sarissa Capital Management LP located in Greenwich Connecticut, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. Alex Denner, Ph.D., is the Founder & Chief Investment Officer of Sarissa Capital Management, an activist firm investing in opportunities crated by the unique dynamics of the healthcare sector. Sarissa founder Alex Denner, who previously worked for Icahn Capital, posted huge gains last year. Dr. Denner has led Sarissa’s involvement in some of biopharma’s most successful strategic transactions and activist campaigns, including the sale of Idenix to Merck, the sale of ARIAD Pharmaceuticals to Takeda and the spinoff from Biogen and subsequent sale of Bioverativ to Sanofi. Prior to founding Sarissa, Denner worked with Carl Icahn and before that was at Viking Global. On ⦠In 2013 he founded Sarissa Capital Management LP, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism ⦠Carl Icahn may have received most of the credit, and certainly the lion's share of the cash, created by his high-profile biotech raiding parties. In 2013 Mr. Denner founded Sarissa Capital Management LP located in Greenwich Connecticut, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Director Dr. Alexander J. Denner acquired 62,800 shares of this biotech company, paying $327.59 per share for a total amount of $20.57 million. Denner left Icahn in 2011 to found Sarissa ⦠Family trees are often presented with the oldest generations at the top and the newer generations at the bottom. Article Written by John Carrol – Fierce Biotech, To read the entire list of the Most Influential People in Biopharama Visit Fierce Biotech. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. “To the extent that they state in their press release that they’re concerned with what investors want, I’ve been told that more value has been created for Ironwood shareholders today than in any single day in history,” he told CNBC. While a representative for Sarissa Capital Management didn’t immediately respond to a request for comment, Dr. Alex Denner told CNBC in an interview on Monday that he hoped “to participate in discussions to maximize value for shareholders.”. Dr. Alex John Denner Alex Denner, Ph.D., has been investing in health-care companies for the past two decades. Infact, the company touted its current nine-member board, saying that their interests were “directly aligned with shareholders.”, “Ironwood Pharmaceuticals maintains open and ongoing communications amongst its shareholders and welcomes new views and opinions that may advance Ironwoods goal of creating shareholder value,” the company said. How can we tell if Regulus Therapeutics Inc (NASDAQ: RGLS) is currently a good investment? Born and raised in... Genealogical data can be represented in several formats, for example as a pedigree or ancestry chart. Ironwoodâs activist investor likes what itâs seen recently from the drugmakerâso much so that it held off on pushing for a spot on the company's board. Denner headed the executive committee that held the wheel, pushing a lead experimental drug–ramucirumab–from Phase I right into late-stage studies. Sarissa Capital was one of ARIAD's largest shareholders and Alex Denner, Ph.D., Sarissa Capital's founder and Chief Investment Officer, was the chairman of ⦠It’s not uncommon to hear news stories using the term Activist Investor when referring to Alex Denner who has a long and successful history of orchestrating sales of biotech firms, like Waltham-based Bioverativ, and Ariad Pharmaceuticals of Cambridge. Shares of Ironwood Pharmaceuticals which makes irritable bowel syndrome drug Linzess, jumped more than 10 percent on Monday, giving it a huge market valuation of $2.4 billion. Alex Denner has been credited as the power behind the throne, a key player in the turnaround story of several top life sciences companies and a figure now promising to start stealing his own headlines now that heâs jumped Icahnâs ship to helm his own hedge fund. Naturally, given Mr. Denner’s considerable healthcare investing experience, Sarissa Capital Management mainly invests in pharmaceutical and biotechnology enterprises. In 2013, he founded Sarissa Capital Management to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the healthcare sector. The two came together at ImClone after both recognized the substantial amount of money that could be made by turning around the troubled company–after CEO Sam Waksal wound up in prison after the notorious insider trading scandal. In addition, Alex makes $422,643 as Independent Director at Biogen. ITRM's staff is compromised of the well known bio legend - Alex Denner who owns Sarissa Capital. Sarissa Capital Management is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,289,695,317 (Form ADV from 2020-03-30). Alex has 4 jobs listed on their profile. Alex Denner (Andrew Harrer/Bloomberg) Sarissa Capital Management is raising money for a new fund.The Tiger Grandcub is launching Sarissa Capital Domestic Fund ⦠“Members of Ironwood Pharmaceuticals management team had one introductory meeting with Sarissa Capital Management representatives prior to Sarissa notifying the company of their intention to nominate a director candidate. The Company's sponsor, Sarissa Capital Acquisition Sponsor LLC (the "Sponsor"), was capitalized by investment funds managed by Sarissa Capital Management LP, which was founded by Alex Denner, Ph.D. Alex Denner is more prominently known as the head of Carl Ichans bio division who spearheaded his portfolio and knows the Bio industry inside/out. Alex Denner is listed as one of the world’s most influential people in biopharma today, in fact Dr.Denner has been investing in health-care companies for the past two decades. These shares were purchased indirectly by Sarissa. “Alex actually understands the science–and how to build that into a business,” ex-con and ImClone founder Sam Waksal told Bloomberg. Alex Denner has extensive experience overseeing the operations and research development of biopharmaceutical companies while evaluating corporate governance matters particularly with respect to broad life sciences. As an inside player, few can compare to Denner. Well-known food blogger Zoe Torinesi of Denner Market inspires you every week with exciting but simple creations and useful kitchen tips and tricks for little... Meet the Denner's John Denner (Piano) and Kate Denner (Vocals) met almost a decade ago and were married on August 21, 2011. Alex Denner, Ph.D., has been investing in health-care companies for the past two decades. And he helped engineer the $6.5 billion sale to Eli Lilly ($LLY) when everyone could focus on the value of Erbitux and its experimental cancer treatments. Alex has a background in biomedical engineering. In 2013, he founded Sarissa Capital Management LP, a registered investment advisor, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the healthcare sector. In 2013 Denner founded Sarissa Capital Management LP located in Greenwich Connecticut, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. A biopharmaceutical, also known as a biologic medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. If Sarissaâs communication turns out to mark the beginning of a protracted proxy battle, Ironwood could be in trouble. Sarissa Capital Management Alex Denner has been investing in healthcare companies for the past two decades. Alex Denner/Sarissa owns 30%. Introducing Adi Denner Adi Denner is an aspiring Opera singer, YA and Fantasy Author, and an Artist. Recently Denner is focusing on another local drugmaker: Ironwood Pharmaceuticals. Denner is also on the boards of drugmakers Vivus Inc. and Biogen Idec Inc., the latter of which he joined while working with billionaire Carl Icahn. “When a company is broken, he knows what should be done to fix it.”. Alex & Sarissa are known from above link and many others of turning Bio companies in to large profitable buyouts. And while he may never make Jim Mullen’s Christmas card list after playing the troublemaker on Biogen Idec’s ($BIIB) board, who can ignore the buoyant honeymoon period that Biogen has enjoyed since the palace coup that led George Scangos into the top office? Working directly under Icahn, it was Denner who played the good cop to Icahn’s bad cop at Genzyme, where he made friends and influenced the raider’s enemies. Alex Denner is one of the most influential people in biopharma history. It upped its bidâand called on activist investor Alex Denner. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. In 2013 he founded Sarissa Capital Management LP, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. Sarissa currently owns 33% of ITRM with a special clause for obtaining 60% total ownership of the outstanding shares. More than half of the smaller slate has ties to activist investor Alex Denner of Sarissa ⦠Sarissa Capitalâs Alex Denner Bullish on Biogen (BIIB) Sarissa Capital Management is a Greenwich, Connecticut-based activist hedge fund established in ⦠This Digital Ninja speaks to 50,000 students (and their parents) & Businesses every... Meet Food Blogger Zoe Torinesi Looking for fresh ideas for a cozy dinner or just looking for something new? Alexander Denner, Ph.D. Chief Investment Officer, Sarissa Capital Management LP. The Digital Ninja Speaker, Author and Trainer, Wayne Denner has spent over 21 years in the digital space using social media, smart phone tech and the internet to his advantage. Alex Denner's hedge fund firm Sarissa Capital has filed a 13D with the SEC regarding shares of Aegerion Pharmaceuticals (AEGR).Per the filing, Sarissa now owns 5.76% of the company with over 1.63 million shares. That was all I needed to know. The Official John Denner Website "All Things Denner. Sarissa focuses on improving the strategies of health-care companies to enhance shareholder value. The Denner's are both professional musicians and chose to use their music as a... Denner Edition Alto recorder after Jacob Denner (Denner-Edition 442) These Amazing Hand-crafted baroque recorders are at the Top of the Class among baroque alto recorders at modern pitch. View Alex Dennerâs profile on LinkedIn, the world's largest professional community. Both were bought out. Denner left Ichan's bio portfolio to spinoff Sarissa Capital and leverage his decades of knowledge.